Targeting ST8SIA6-AS1 Counteracts KRAS Inhibitor Resistance Through Abolishing the Reciprocal Activation of PLK1/c-Myc Signaling

Overview

Journal Exp Hematol Oncol

Publisher Biomed Central

Specialty Hematology

Date 2023 Dec 16

PMID 38104151

Authors

Yafang Wang

Mingyue Yao

Cheng Li

Kexin Yang

Xiaolong Qin

Lansong Xu

Shangxuan Shi

Chengcheng Yu

Xiangjun Meng

Chengying Xie

Affiliations

Soon will be listed here.

Abstract

Background: KRAS inhibitors (KRASi) AMG510 and MRTX849 have shown promising efficacy in clinical trials and been approved for the treatment of KRAS-mutant cancers. However, the emergence of therapy-related drug resistance limits their long-term potential. This study aimed to identify the critical mediators and develop overcoming strategies.

Methods: By using RNA sequencing, RT-qPCR and immunoblotting, we identified and validated the upregulation of c-Myc activity and the amplification of the long noncoding RNA ST8SIA6-AS1 in KRASi-resistant cells. The regulatory axis ST8SIA6-AS1/Polo-like kinase 1 (PLK1)/c-Myc was investigated by bioinformatics, RNA fluorescence in situ hybridization, RNA immunoprecipitation, RNA pull-down and chromatin immunoprecipitation. Gain/loss-of-function assays, cell viability assay, xenograft models, and IHC staining were conducted to evaluate the anti-cancer effects of co-inhibition of ST8SIA6-AS1/PLK1 pathway and KRAS both in vitro and in vivo.

Results: KRASi sustainably decreased c-Myc levels in responsive cell lines but not in cell lines with intrinsic or acquired resistance to KRASi. PLK1 activation contributed to this ERK-independent c-Myc stability, which in turn directly induced PLK1 transcription, forming a positive feedback loop and conferring resistance to KRASi. ST8SIA6-AS1 was found significantly upregulated in resistant cells and facilitated the proliferation of KRAS-mutant cancers. ST8SIA6-AS1 bound to Aurora kinase A (Aurora A)/PLK1 and promoted Aurora A-mediated PLK1 phosphorylation. Concurrent targeting of KRAS and ST8SIA6-AS1/PLK1 signaling suppressed both ERK-dependent and -independent c-Myc expression, synergistically led to cell death and tumor regression and overcame KRASi resistance.

Conclusions: Our study deciphers that the axis of ST8SIA6-AS1/PLK1/c-Myc confers both intrinsic and acquired resistance to KRASi and represents a promising therapeutic target for combination strategies with KRASi in the treatment of KRAS-mutant cancers.

Citing Articles

IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response.

Yao M, Yan W, Wang Y, Zhao Y, Xu X, Chen Y Exp Hematol Oncol. 2025; 14(1):15.

PMID: 39955584 PMC: 11829435. DOI: 10.1186/s40164-025-00605-y.

Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemia.

Chen Y, Zhao Y, Yao M, Wang Y, Ma M, Yu C Acta Pharmacol Sin. 2025; .

PMID: 39885312 DOI: 10.1038/s41401-025-01479-w.

Crispr-Cas9-based long non-coding RNA interference and activation identified that the aberrant expression of Myc-regulated ST8SIA6 antisense RNA 1 promotes tumorigenesis and metastasis in hepatocellular carcinoma.

Liu X, Jiang D, Liu Y, Xie K, Zhao Y, Liu F Cytojournal. 2024; 21:53.

PMID: 39737136 PMC: 11683396. DOI: 10.25259/Cytojournal_109_2024.

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia.

Luo Z, Lin C, Yu C, Yuan C, Wu W, Xu X Cancer Res. 2024; 85(1):101-117.

PMID: 39437162 PMC: 11694061. DOI: 10.1158/0008-5472.CAN-24-1093.

Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS-mutant Cancers.

Wang Y, Xu L, Ling L, Yao M, Shi S, Yu C Adv Sci (Weinh). 2024; 11(41):e2404926.

PMID: 39254172 PMC: 11538672. DOI: 10.1002/advs.202404926.

References

Huang H, Weng H, Chen J . mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020; 37(3):270-288. PMC: 7141420. DOI: 10.1016/j.ccell.2020.02.004. View

Tse A, Schwartz G . Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic.... Cancer Res. 2004; 64(18):6635-44. DOI: 10.1158/0008-5472.CAN-04-0841. View

Wang D, Qian G, Zhang H, Magliocca K, Nannapaneni S, Amin A . HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. Clin Cancer Res. 2016; 23(3):677-686. PMC: 5199640. DOI: 10.1158/1078-0432.CCR-16-0558. View

Weiss A, Lorthiois E, Barys L, Beyer K, Bomio-Confaglia C, Burks H . Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022; 12(6):1500-1517. PMC: 9394399. DOI: 10.1158/2159-8290.CD-22-0158. View

Wang Y, Fang Z, Hong M, Yang D, Xie W . Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B. 2020; 10(1):105-112. PMC: 6976993. DOI: 10.1016/j.apsb.2019.09.011. View

Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J . PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018; 128(12):5517-5530. PMC: 6264635. DOI: 10.1172/JCI122533. View

Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X . A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015; 27(3):370-81. DOI: 10.1016/j.ccell.2015.02.004. View

Bang D, Wilson W, Ryan M, Yeh J, Baldwin A . GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB. Cancer Discov. 2013; 3(6):690-703. PMC: 3679268. DOI: 10.1158/2159-8290.CD-12-0541. View

Sharma G, Okada Y, Von Hoff D, Goel A . Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. Semin Cancer Biol. 2020; 75:153-168. PMC: 8035348. DOI: 10.1016/j.semcancer.2020.10.001. View

10.

Fakih M, Kopetz S, Kuboki Y, Kim T, Munster P, Krauss J . Sotorasib for previously treated colorectal cancers with KRAS mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2021; 23(1):115-124. DOI: 10.1016/S1470-2045(21)00605-7. View

11.

Chen B, Dragomir M, Fabris L, Bayraktar R, Knutsen E, Liu X . The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology. 2020; 159(6):2146-2162.e33. PMC: 7725986. DOI: 10.1053/j.gastro.2020.08.018. View

12.

Armaos A, Colantoni A, Proietti G, Rupert J, Tartaglia G . catRAPID omics v2.0: going deeper and wider in the prediction of protein-RNA interactions. Nucleic Acids Res. 2021; 49(W1):W72-W79. PMC: 8262727. DOI: 10.1093/nar/gkab393. View

13.

Hayes T, Neel N, Hu C, Gautam P, Chenard M, Long B . Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell. 2016; 29(1):75-89. PMC: 4816652. DOI: 10.1016/j.ccell.2015.11.011. View

14.

Li Z, Zhang C, Zong X, Wang Z, Ren R, Wang L . ST8SIA6-AS1 Promotes the Epithelial-to-Mesenchymal Transition and Angiogenesis of Pituitary Adenoma. J Oncol. 2022; 2022:7960261. PMC: 9242794. DOI: 10.1155/2022/7960261. View

15.

Xue J, Zhao Y, Aronowitz J, Mai T, Vides A, Qeriqi B . Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020; 577(7790):421-425. PMC: 7308074. DOI: 10.1038/s41586-019-1884-x. View

16.

Zhang Y, Du X, Wang C, Lin D, Ruan X, Feng Y . Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells. Gastroenterology. 2011; 142(3):521-530.e3. DOI: 10.1053/j.gastro.2011.11.023. View

17.

Wu M, Lu L, Dai T, Li A, Yu Y, Li Y . Construction of a lncRNA-mediated ceRNA network and a genomic-clinicopathologic nomogram to predict survival for breast cancer patients. Cancer Biomark. 2023; 36(1):83-96. DOI: 10.3233/CBM-210545. View

18.

Zhang B, Liu Z, Liu J, Cao K, Shan W, Wen Q . Long non‑coding RNA ST8SIA6‑AS1 promotes the migration and invasion of hypoxia‑treated hepatocellular carcinoma cells through the miR‑338/MEPCE axis. Oncol Rep. 2021; 45(1):73-82. PMC: 7709816. DOI: 10.3892/or.2020.7864. View

19.

Silvis M, Silva D, Rohweder R, Schuman S, Gudipaty S, Truong A . MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. J Exp Med. 2023; 220(3). PMC: 9930170. DOI: 10.1084/jem.20221524. View

20.

Qin S, Zhou H, Xu N, Yang H, Chen P . The Diagnostic Value of Serum ST8SIA6-AS1 as Biomarker in Hepatocellular Carcinoma. Clin Lab. 2020; 66(12). DOI: 10.7754/Clin.Lab.2020.200231. View